Large Cell and Small Cell Neuroendocrine Bladder Carcinoma Immunohistochemical and Outcome Study in a Single Institution
|
|
- Sophia Greer
- 6 years ago
- Views:
Transcription
1 Anatomic Pathology / NEUROENDOCRINE BLADDER CARCINOMA Large Cell and Small Cell Neuroendocrine Bladder Carcinoma Immunohistochemical and Outcome Study in a Single Institution Francisco Alijo Serrano, MD, 1 Nora Sánchez-Mora, MD, PhD, 1,2 José Angel Arranz, MD, PhD, 3 Carlos Hernández, MD, PhD, 4 and Emilio Álvarez-Fernández, MD, PhD 1 Key Words: Small cell bladder carcinoma; Immunohistochemical profile; Survival Abstract We studied 44 cases of small cell bladder carcinoma (SCBC) and 2 cases of large cell neuroendocrine bladder carcinoma (LCNBC) to determine the immunohistochemical profile and biologic behavior. Thyroid transcription factor (TTF)-1, cytokeratin (CK)20, chromogranin A (CgA), synaptophysin, neuron-specific enolase (NSE), and Leu- 7 studies were performed. TTF-1+ cases were stained for surfactant protein A (SP-A). The immunohistochemical profile for 44 SCBC cases was as follows: TTF-1+, 11 (25%); CK20+, 3 (7%); CgA+, 13 (30%); synaptophysin+, 22 (50%); NSE+, 35 (80%); and Leu-7+, 30 (68%), and for 2 LCNBC cases was as follows: TTF-1+, 2 (100%); CgA+, (50%); synaptophysin+, 1 (50%); NSE+, 2 (100%); and Leu- 7+, 2 (100%). All cases with TTF-1 expression were negative for SP-A, except 1 case. This case was a mixed SCBC with TTF-1 expression in the urothelial component, which also expressed SP-A. Immunohistochemical markers were not associated with survival. The prognosis of SCBC is relatively better than its pulmonary counterpart. LCNBC seems to be a rarely recognized entity. TTF-1 expression is not limited to small cell lung carcinoma. Extrapulmonary small cell carcinoma is a rare but wellcharacterized tumor occurring at sites as diverse as the gastrointestinal tract, thymus, larynx, salivary gland, skin, breast, prostate, and cervix. 1-7 Small cell bladder carcinoma (SCBC) is very uncommon, accounting for fewer than 1% of all urinary bladder carcinomas, 8,9 and has a poor prognosis, as does its pulmonary counterpart. 8,10-12 This neoplasm is associated with tobacco smoking and frequently seems associated with other carcinomatous components, such as urothelial carcinoma, adenocarcinoma, sarcomatoid carcinoma, or mixtures of these components. 12,13 In addition to SCBC, primary large cell neuroendocrine bladder carcinoma (LCNBC) has been recognized more recently. There are only 8 cases reported in the literature. 14 Immunohistochemical markers commonly used to demonstrate neuroendocrine differentiation, such as chromogranin, synaptophysin, and neuron-specific enolase (NSE), are variably expressed by SCBC. 15 The expression of thyroid transcription factor (TTF)-1 by SCBC has been reported by Jones et al 16 and Soriano et al 17 in series of 44 and 10 cases, respectively. No previous report has been found concerning the expression of surfactant protein A (SP-A). A Merkel cell carcinoma like immunophenotype with positive expression of cytokeratin (CK)20 had been reported in extrapulmonary small cell carcinoma Some reports suggested that Merkel cell carcinoma like CK20+ salivary gland small cell carcinomas have a better prognosis than CK20 tumors. 18,19 The aim of our work was to study the immunohistochemical expression of TTF-1, SP-A, CK20, chromogranin A (CgA), synaptophysin, NSE, and Leu-7 in a series of 46 cases: 44 cases of SCBC and 2 cases of LCNBC from a single institution to further elucidate the immunohistochemical Am J Clin Pathol 2007;128:
2 Alijo Serrano et al / NEUROENDOCRINE BLADDER CARCINOMA profile and the biologic behavior according to the expression of these markers. Materials and Methods Clinical data for 44 patients with SCBC and 2 with LCNBC were reviewed for clinical information and follow-up status. All tumors were classified according to criteria established by the World Health Organization classification system. 21 The 2002 TNM classification system was used for pathologic staging. Archival materials from these 46 cases (accessioned from January 1990 to December 2005) were retrieved from the surgical pathology files of the Gregorio Marañón University General Hospital, Madrid, Spain. For light microscopy, 4-µm sections were cut from paraffin blocks and stained with H&E. Histologic slides were reviewed at least 3 times by all 3 pathologist participants in the study (F.A.S., N.S.-M., and E.Á.-F.). All tumors fulfilled the criteria established for small cell carcinoma according to the World Health Organization classification system. Additional sections were obtained for immunohistochemical staining, which was performed on an automatic immunostainer (TechMate 500, DAKO, Carpinteria, CA). All cases were stained for TTF-1, CK20, CgA, synaptophysin, NSE, and Leu- 7. Cases with TTF-1 expression were also stained for SP-A. Immunohistochemical stains for TTF-1 were carried out using monoclonal mouse anti TTF-1 antibody (clone SPT24, 1:100 dilution; Novocastra, Newcastle upon Tyne, England), CK20 (clone Ks20.8, 1:50 dilution; Novocastra), CgA (clone LK2H10, 1:2 dilution; DAKO, Carpinteria, CA), synaptophysin (polyclonal, 1:8 dilution; Biomeda, Foster City, CA), NSE (clone BBS/NC/VI-H14, DAKO); Leu-7 (clone HNK-1, 1:20 dilution; Becton Dickinson, San Jose, CA); and SP-A (clone PE10, 1:80 dilution; DAKO). Statistical Analysis Individual information and baseline characteristics were summarized using descriptive statistics. Comparison of proportions was performed with the χ 2 according to the Yates test or Fisher exact test (for cross-tabulations with an expected value in any cell δ5). Test results were considered significant if 2-tailed P values were less than.05. Survival was measured from the time of diagnosis to the date of death or the latest follow-up. Overall survival was estimated using the Kaplan- Meier method. Statistical analyses were performed using SPSS software (version 11.5, SPSS, Chicago, IL). Results Table 1 summarizes relevant clinical data for the cases studied. Of the patients, 41 (89%) were men and 5 (11%) were women. The average age was 69.7 years (range, years; SD, 11.9 years). Tobacco use was reported by 33 patients (72%) and denied by 13 (28%). Tobacco consumption was more frequent in men (P =.001). All cases were treated by surgery (27 by transurethral resection and 19 by radical cystoprostatectomy). In addition to surgery, 20 (43%) of 46 cases received chemotherapy, 12 (26%) received radiotherapy, and 3 (7%) received palliative treatment. Of the 46 tumors, 28 (61%) were located in the posterior vesicle wall, 12 (26%) in the lateral walls, and 6 (13%) in the anterior wall. Histologically, 28 (61%) of 46 tumors showed a homogeneous, pure microcytic pattern Image 1A. In 16 cases (35%), an additional urothelial component was also observed, and 2 cases (4%) fulfilled the histologic criteria for LCNBC characterized by large, polygonal cells with a low nuclear/cytoplasmic ratio. Coarse chromatin and frequent nucleoli, mitotic activity in excess of 10 mitoses per 10 high-power fields, and multiple areas of necrosis were also seen Image 1B. Pathologic staging was I in 4 (9%) of 46 cases, II in 21 (46%), III in 12 (26%), and IV in 9 (20%). Among the 46 cases, 13 (28%) showed positive staining for TTF-1 (11/44 SCBC; 2/2 LCNBC) Image 1C. These cases were 9 pure small cell carcinomas, 2 small cell carcinomas with a urothelial carcinoma component, and 2 LCNBCs. All cases with TTF-1 expression were negative for SP-A, except 1 case (8%). This case was a small cell carcinoma with TTF-1 expression in the urothelial component, which also expressed SP-A Image 1D and Image 1E. CK20 expression was observed in 3 cases (7%). The positive stain was diffuse in the cytoplasm. Neuroendocrine marker expression was as follows: NSE+, 37 (80%; 35/44 SCBC; 2/2 LCNBC); CgA+, 14 (30%; 13/44 SCBC; 1/2 LCNBC); synaptophysin+, 23 (50%; 22/44 SCBC; 1/2 LCNBC); and Leu-7+, 32 (70%; 30/44 SCBC; 2/2 LCNBC) Table 2. None of the immunohistochemical markers used in our study showed significant statistical correlation with any of the clinical parameters analyzed. Follow-up information was available for all cases. The mean follow-up was 20.1 months (δ = 27.5; range, months). The 3-year survival rate was 27.5%. The mean survival for the whole series was 40 months (95% confidence interval [CI], months). Of the 46 patients, 29 (63%) died of disease, 7 (15%) were alive with tumor (local relapse: 2 patients with urothelial carcinoma, 4 with metastatic disease, and 1 with lung adenocarcinoma), and 10 (22%) were alive without evidence of disease after 5 years of follow-up. The 3-year survival rate by stage was as follows: I, 100%; II, 58%; III, 47%; and IV, 4%. The overall 5-year survival rate by stage was as follows: I, 100%; II, 39% (mean, 51 months; 95% CI, months); III, 46.8% (mean, 33 months; 95% CI, months); and IV, 4% (mean, Am J Clin Pathol 2007;128: Downloaded 734 from
3 Anatomic Pathology / ORIGINAL ARTICLE Table 1 Clinical and Pathologic Characteristics of 46 Patients With Small Cell Bladder Carcinoma Case No/Sex/Age (y) TNM Stage Histologic Type Treatment Survival (mo)/status 1/M/61 II Microcytic, mixed RCP 9/AWD 2/F/60 I Microcytic, pure TUR 4/AWD 3/M/80 II Microcytic, mixed TUR 4/AWD 4/M/85 II Microcytic, pure TUR 3/DOD 5/M/58 I Microcytic, mixed TUR, RT, CH 3/AD 6/M/65 IV Microcytic, pure TUR 12/DOD 7/M/78 III Microcytic, pure RCP 20/AD 8/F/77 IV Microcytic, mixed TUR, RT 2/DOD 9/M/75 III Microcytic, pure TUR, CH 30/DOD 10/M/71 II Microcytic, pure TUR, RT, CH 16/AD (urothelial carcinoma) 11/M/40 II LCNBC RCP, CH 13/AWD 12/M/76 III Microcytic, pure RCP, RT, CH 31/AWD 13/M/58 IV Microcytic, mixed RCP 13/DOD 14/M/73 II Microcytic, pure TUR 1/DOD 15/M/46 III Microcytic, pure RCP, CH 29/AWD 16/M/61 II Microcytic, pure TUR, RT 7/DOD 17/M/58 IV Microcytic, mixed RCP, CH 9/DOD 18/M/67 IV Microcytic, mixed RCP, CH 21/DOD 19/M/75 IV Microcytic, pure TUR, RT 3/DOD 20/M/70 III Microcytic, mixed RCP 3/DOD 21/M/77 I Microcytic, pure RCP, CH 37/AWD 22/F/78 II Microcytic, mixed TUR 5/DOD 23/M/82 III Microcytic, mixed RCP, CH 17/DOD 24/M/70 IV Microcytic, pure TUR, CH 31/DOD 25/M/68 III Microcytic, pure RCP, CH 44/AWD 26/M/80 IV Microcytic, pure TUR, palliative 8/DOD 27/M/77 IV Microcytic, pure RCP, RT 16/DOD 28/F/43 IV LCNBC RCP, RT 12/DOD 29/M/75 IV Microcytic, pure TUR, RT, CH 27/DOD 30/M/85 I Microcytic, mixed TUR 57/AD (urothelial carcinoma) 31/M/79 IV Microcytic, pure TUR, RT 8/DOD 32/M/75 IV Microcytic, pure TUR 2/DOD 33/F/40 II Microcytic, mixed RCP, CH 87/AD 34/M/65 II Microcytic, pure TUR 12/DOD 35/M/80 II Microcytic, mixed TUR, RT 47/DOD 36/M/73 II Microcytic, mixed TUR, CH 98/AD (lung carcinoma) 37/M/69 IV Microcytic, pure RCP, CH 2/DOD 38/M/74 IV Microcytic, pure TUR, CH 6/DOD 39/M/78 IV Microcytic, pure TUR, palliative 24/DOD 40/M/54 IV Microcytic, pure RCP, CH 120/AWD 41/M/79 IV Microcytic, pure TUR 1/DOD 42/M/79 III Microcytic, mixed TUR, RT 12/DOD 43/M/65 IV Microcytic, pure RCP, CH 2/DOD 44/M/59 IV Microcytic, pure RCP, CH 14/DOD 45/M/89 IV Microcytic, pure TUR, palliative 1/AD 46/M/82 II Microcytic, mixed TUR 1/AWD AD, alive with disease; AWD, alive without disease; CH, chemotherapy; DOD, died of disease; LCNBC, large cell neuroendocrine bladder carcinoma; RCP, radical cystoprostatectomy; RT, radiotherapy; TUR, transurethral resection. months; 95% CI, 5-27 months). Among the 9 patients with stage IV disease, 1 with metastatic disease at diagnosis underwent radical cystoprostatectomy after complete remission to chemotherapy. This patient was alive and free of disease more than 10 years following cystectomy. The clinicopathologic variables studied were age, sex, smoking history, histologic tumor type, use of chemotherapy and radiation therapy, and immunohistochemical markers (CgA, synaptophysin, NSE, Leu-7, and TTF-1). We found no statistically significant differences associated with survival. The TNM stage was the only prognostic factor with a statically significant relationship to survival (log rank, 0.002). Discussion Small cell carcinoma is an uncommon tumor in the bladder. The prognosis for SCBC is generally poor. 8,10-12 However, a relatively better survival for patients with bladder cancer than that of the pulmonary counterpart has been reported. There are only 19 reports of SCBC series that include at least 10 patients. 7,8,11-17,22-31 According to these reports, the 5-year survival rate for all stages is variable, ranging between 8% and 40% Table 3. When comparing the survival rate of our series with the only published report in which the cases were properly staged, 23 a certain similarity of Am J Clin Pathol 2007;128:
4 Alijo Serrano et al / NEUROENDOCRINE BLADDER CARCINOMA A B C D E Image 1 A, Section of small cell bladder carcinoma showing rosette formation (H&E, original magnification 20). B, Large cell neuroendocrine bladder carcinoma showing palisading at the periphery of the nest of tumor cells with central necrosis. Large tumor cells have abundant cytoplasm with large nuclei, vesicular nuclear chromatin, and prominent nucleoli. No glandular or squamous differentiation is seen (H&E, original magnification 20). C, Immunostaining for thyroid transcription factor (TTF)-1 in small cell bladder carcinoma (original magnification 20). D, Immunostaining for surfactant protein A in the urothelial component (original magnification 10). E, Immunostaining for TTF-1 in a case with mixed small cell papillary urothelial bladder carcinoma showing TTF-1 nuclear expression in the urothelial component (original magnification 20). survival can be found. The 5-year rates for patients with stage II, III, and IV disease were 63.6%, 15.4%, and 10.5%, respectively. In our series, the survival rate with stage I tumors was 100%; for stage II, 39%; for stage III, 47%; and for stage IV, 4%. The outcome is relatively better for SCBC than for small cell lung carcinoma. One possible explanation is that tumor volume may be smaller in SCBC than in small cell lung cancer of limited stage at the time of diagnosis.27 It is important to mention that there are some reported cases of stage IV SCBC that showed a long-term survival31 like one 736 Am J Clin Pathol 2007;128: Downloaded 736 from of our cases. This has not been previously described in small cell lung carcinoma. Primary LCNBC represents a rare and new histologic tumor type. We found 2 cases of pure primary LCNBC. The clinical behavior trends are similar to those of SCBC in the only 8 cases previously reported14 and both cases reported by us. The diagnosis of SCBC can be made on morphologic grounds alone, even if neuroendocrine differentiation cannot be demonstrated.21 In addition, a novel immunohistochemical marker, TTF-1, has been demonstrated in this tumor. Cheuk et
5 Anatomic Pathology / ORIGINAL ARTICLE Table 2 Immunohistochemical Profile of Small Cell Bladder Carcinoma in Different Studies * Neuron-Specific Thyroid Transcription Study No. of Cases Enolase Chromogranin A Synaptophysin Leu-7 Factor-1 Present study, (80) 14 (30) 23 (50) 32 (70) 13 (28) Abrahams et al, Jones et al, Soriano et al, Helpap, Nabi et al, Trias et al, Iczkowski et al, Abbas et al, Grignon et al, Blomjous et al, Mills et al, * Data are given as number (percentage) or percentage of positive cases. Table 3 Small Cell Bladder Carcinoma: A Review of Case Series With 10 or More Cases No. of Source of Overall Survival (%)/ Study Cases Cases * Follow-up Survival Quek et al, /2 y; 10/5 y Median, 13 mo Abrahams et al, /5 y Median, 23 mo Wang et al, /2 y; 16/5 y Jones et al, /5 y Choong et al, Stage II, 63.6/5 y; stage III, Mean, 1.7 y 15.4/5 y; stage IV, 10.5/5 y Bex et al, Median, 8 mo (range, 2-84 mo); limited disease, 12 mo (range, 4-84 mo); extensive disease, 5 mo (range, 2-17 mo) Mangar et al, Cases referred 24/2 y Median, 5 mo to 1 hospital Cheng et al, /3 y; 16/5 y Soriano et al, Mean, 8.7 mo Helpap, Own and Mean, 6.9 mo consultation cases Nabi et al, Mean, 16.5 mo (range, 6-30 mo) Trias et al, /6.2 mo Lohrisch et al, Cases referred All groups, 36/5 y; limited Mean, 47 mo (95% confidence interval, to 1 hospital stage, 44/5 y ); median, 41 mo Iczkowski et al, /5 y Mean, 17 mo (range, mo) Abbas et al, Compiled all cases 25/2 y; 8/5 y Mean, 19.6 mo (range, 0-18 y) published until 1995 Holmang et al, Autopsy, 3 cases; extensive disease, 4 cases; limited disease, 18 cases; 13 died of progressive disease (mean, 7.3 mo); 5 alive without disease (median, 10 y) Grignon et al, Mean, 9.8 mo (range, 2-21 mo); median, 10 mo Blomjous et al, (78%) died of tumor (mean, 9.5 mo); 3 alive at 22, 23, and 38 mo; 1 alive at 5 y Mills et al, Median, 4 mo (range, mo) * The number of hospitals is given unless otherwise indicated. al 32 and Agoff et al 33 reported TTF-1 expression in 1 of 3 and 2 of 4 cases of SCBC, respectively, and Jones et al, 16 in a series of 44 cases of SCBC, demonstrated TTF-1 expression in 17 cases (39%). In our study, TTF-1 expression was seen in 27% (12/44) of the cases of SCBC. TTF-1 immunoreactivity showed no correlation with any of the clinical parameters analyzed. It is important to mention that expression of TTF-1 and SP-A was also observed in the non small cell component of 1 case. This finding has not been reported previously. Unexpected expression of SP-A has been reported in other studies, including 3 cases of thyroid carcinoma, 6 of prostatic carcinoma, 34 and 6 of breast carcinoma 35 but not in primary bladder carcinoma. All these cases were reported in pulmonary metastases from the tumors. This raised doubt about whether the positive expression of the SP-A is a result of its synthesis by tumor cells or of phagocytosis of the SP-A by tumor cells. Only 1 case of extrapulmonary primary colorectal carcinoma expressing Am J Clin Pathol 2007;128:
6 Alijo Serrano et al / NEUROENDOCRINE BLADDER CARCINOMA SP-A has been reported previously. 36 The possible explanation for this could be the relationship of the biochemical structure of SP-A with a number of cellular proteins that share homology with its molecule, like calcium-dependent lectins and type-iv collagen. 37,38 This coexpression of TTF-1 and SP- A must be considered when evaluating carcinomas of unknown origin appearing clinically as disseminated disease. One pure and one mixed small cell carcinoma recurred as purely papillary carcinoma. The recurrent tumors did not show neuroendocrine markers or TTF-1. In addition to studying the expression of TTF-1 in SCBC, we also examined the expression of CgA, synaptophysin, NSE, Leu-7, and SP-A in this group of tumors. None showed any relationship with survival. The only prognostic factor for survival was the TNM classification. CK20 expression has also been shown to be a useful marker in distinguishing Merkel cell carcinoma from small cell carcinoma. However frequent CK20 positivity was observed in salivary gland small cell carcinomas, suggesting that may be a subtype of Merkel cell carcinoma with clinical evolution that is less aggressive than other small cell carcinomas. 18,19 CK20 expression also had been reported in vaginal small cell carcinoma in 1 case. 20 Because the prognosis for SCBC is relatively better than that of its pulmonary counterpart, we studied CK20 expression as a possible marker with clinical significance. Our results showed expression in only 3 cases, and the pattern of staining was diffuse cytoplasmic and without prognostic significance. Therefore CK20 expression did not prove to be a diagnostic or prognostic marker for SCBC in our study. The prognosis of SCBC seems to be relatively better than that of its pulmonary counterpart, especially in stage I tumors. This probably justifies aggressive therapy from the beginning. SCBCs expressed neuroendocrine markers, but the markers do not bear prognostic significance. The expression of TTF-1 must be kept in mind if SCC appears as disseminated neoplasia from an unknown primary site. Finally, the expression SP- A in the papillary component and recurrence with purely papillary morphologic features emphasized the necessity to clarify the natural history of this neoplasia. From the Departments of 1 Pathology, 3 Oncology, and 4 Urology, Gregorio Marañón University General Hospital, Madrid Spain; and 2 LABIEMET, Universidad de Los Andes, Táchira, Venezuela. Address reprint requests to Dr Alijo Serrano or Dr Álvarez- Fernández: Hospital General Universitario Gregorio Marañón, C/ Dr Esquerdo No. 46, Dpto de Anatomía Patológica, CP, 28007, Madrid, Spain. References 1. Sarma DP. Oat cell carcinoma of the esophagus. J Surg Oncol. 1982;19: Wick MR, Scheithauer BW. Oat-cell carcinoma of the thymus. Cancer. 1982;49: Porto DP, Wick MR, Ewing SL, et al. Neuroendocrine carcinoma of the larynx. Am J Otolaryngol. 1987;8: Gnepp DR, Wick MR. Small cell carcinoma of the major salivary glands: an immunohistochemical study. Cancer. 1990;66: Taxy JB, Ettinger DS, Wharam MD. Primary small cell carcinoma of the skin. Cancer. 1980;46: Yogore MG III, Saghal S. Small cell carcinoma of the male breast: report of a case. Cancer. 1977;39: Abbas F, Civantos F, Benedetto P, et al. Small cell carcinoma of the bladder and prostate. Urology. 1995;46: Blomjous CE, Vos W, De Voogt HJ, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer. 1989;64: Lopez JI, Angulo JC, Flores N, et al. Small cell carcinoma of the urinary bladder: a clinicopathological study of six cases. Br J Urol. 1994;73: Mackey JR, Au HJ, Hugh J, et al. Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J Urol. 1998;159: Grignon DJ, Ro JY, Ayala AG, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 22 cases. Cancer. 1992;69: Cheng L, Pan CX, Yang XJ, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004;101: Wang L, Jones TD, Maclennan GT, et al. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications. Anticancer Res. 2005;25: Quek ML, Nichols PW, Yamzon J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the University of Southern California experience. J Urol. 2005;174: Mangar SA, Logue JP, Shanks JH, et al. Small-cell carcinoma of the urinary bladder: 10-year experience. Clin Oncol (R Coll Radiol). 2004;16: Jones TD, Kernek KM, Yang XJ, et al. Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol. 2005;36: Soriano P, Navarro S, Gil M, et al. Small-cell carcinoma of the urinary bladder: a clinico-pathological study of ten cases. Virchows Arch. 2004;445: Chan JK, Suster S, Wenig BM, et al. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol. 1997;21: Bobos M, Hytiroglou P, Kostopoulos I, et al. Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung. Am J Dermatopathol. 2006;28: Coleman NM, Smith-Zagone MJ, Tanyi J, et al. Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype. Am J Surg Pathol. 2006;30: Eble JN, Sauter G, Epstein JI, et al, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; World Health Organization Classification of Tumours. 22. Trias I, Algaba F, Condom E, et al. Small cell carcinoma of the urinary bladder: presentation of 23 cases and review of 134 published cases. Eur Urol. 2001;39: Am J Clin Pathol 2007;128: Downloaded 738 from
7 Anatomic Pathology / ORIGINAL ARTICLE 23. Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder: the Mayo Clinic experience. Cancer. 2005;103: Bex A, Nieuwenhuijzen JA, Kerst M, et al. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology. 2005;65: Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer. 2002;95: Nabi G, Singh I, Ansari MS, et al. Primary small cell neuroendocrine carcinoma of urinary bladder: an uncommon entity to be recognized. Int Urol Nephrol. 2001;33: Lohrisch C, Murray N, Pickles T, et al. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer. 1999;86: Iczkowski KA, Shanks JH, Allsbrook WC, et al. Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense gamma-enolase expression. Histopathology. 1999;35: Holmang S, Borghede G, Johansson SL. Primary small cell carcinoma of the bladder: a report of 25 cases. J Urol. 1995;153: Mills SE, Wolfe JT III, Weiss MA, et al. Small cell undifferentiated carcinoma of the urinary bladder: a lightmicroscopic, immunocytochemical, and ultrastructural study of 12 cases. Am J Surg Pathol. 1987;11: Abrahams NA, Moran C, Reyes AO, et al. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology. 2005;46: Cheuk W, Kwan MY, Suster S, et al. Immunostaining for thyroid transcription factor 1 and cytokeratin 20 aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas. Arch Pathol Lab Med. 2001;125: Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13: Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36: Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9: Zamecnik J, Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch. 2002;440: Floros J, Phelps DS, Kourembanas S, et al. Primary translation products, biosynthesis, and tissue specificity of the major surfactant protein in rat. J Biol Chem. 1986;261: Phelps DS, Harding HP. Immunohistochemical localization of a low molecular weight surfactant-associated protein in human lung. J Histochem Cytochem. 1987;35: Am J Clin Pathol 2007;128:
Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature
ISPUB.COM The Internet Journal of Urology Volume 7 Number 1 Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature T Hsieh, J Aragon-Ching, J Saia, T Sotelo Citation T
More informationChapter 4: Small Cell Carcinoma of the Bladder: A Single Centre Study of 25 Cases Treated in Analogy to Small Cell Lung Cancer
Chapter 4: Small Cell Carcinoma of the Bladder: A Single Centre Study of 25 Cases Treated in Analogy to Small Cell Lung Cancer A. Bex J.A. Nieuwenhuijzen J.M. Kerst F. Pos H. van Boven W. Meinhardt S.
More informationMINI-REVIEW. of the Literature. Sarabjeet Chhabra 1 *, Padmaraj Hegde 1, Paras Singhal 2. Abstract. Introduction. Characteristics of SCCB
MINI-REVIEW Primary Small Cell Carcinoma of the Urinary Bladder - Minireview of the Literature Sarabjeet Chhabra 1 *, Padmaraj Hegde 1, Paras Singhal 2 Abstract Primary small cell carcinoma of urinary
More informationCytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis
https://doi.org/10.1186/s13104-018-3319-4 BMC Research Notes RESEARCH NOTE Open Access Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis Atif Ali
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More information2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE. Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT
2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT 2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE AUTHORS : PROSTATE CHAPTER
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationsarcomatoid carcinoma with small cell carcinoma component of the urinary bladder: a case report with review of the literature
Int J Clin Exp Pathol 2013;6(8):1671-1676 www.ijcep.com /ISSN:1936-2625/IJCEP1306009 Case Report Sarcomatoid carcinoma with small cell carcinoma component of the urinary bladder: a case report with review
More informationClinical analysis of small cell carcinoma of the bladder in Chinese: nine case reports and literature reviews
Chen et al. World Journal of Surgical Oncology (2017) 15:33 DOI 10.1186/s12957-016-1079-y RESEARCH Clinical analysis of small cell carcinoma of the bladder in Chinese: nine case reports and literature
More informationDisclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility
The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,
More informationBJUI. Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology SMALL CELL CARCINOMA OF THE URINARY BLADDER MUKESH et al. BJUI BJU INTERNATIONAL Small cell carcinoma of the urinary bladder: a 15-year
More informationSmall-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases
Virchows Arch (2004) 445:292 297 DOI 10.1007/s00428-004-1041-1 ORIGINAL ARTICLE P. Soriano S. Navarro M. Gil A. Llombart-Bosch Small-cell carcinoma of the urinary bladder. A clinico-pathological study
More informationAmerican Journals of Cancer Case Reports. A Rare Case of Rectal Metastasis from Sarcomatoid Variant of Urothelial Carcinoma: A Case Report
American Journals of Cancer Case Reports Lin JYJ et al. American Journals of Cancer Case Reports 2014, 3:1-5 http://ivyunion.org/index.php/ajccr Page 1 of 5 Vol 3 Article ID 20140539, 5 pages Case Report
More informationPrimary small cell carcinoma of the urinary bladder: a 10-year retrospective review of treatment and survival at a single institution.
Biomedical Research 2018; 29 (9): 1815-1821 ISSN 0970-938X www.biomedres.info Primary small cell carcinoma of the urinary bladder: a 10-year retrospective review of treatment and survival at a single institution.
More informationPrimary Large-Cell Neuro-Endocrine Carcinoma of the Bladder: The Study of Two Cases with the Literature Review
Article ID: WMC003138 ISSN 2046-1690 Primary Large-Cell Neuro-Endocrine Carcinoma of the Bladder: The Study of Two Cases with the Literature Review Corresponding Author: Dr. Mohamed H Benazzouz, Resident,
More informationBasaloid Carcinoma of the Lung: A Really Dismal Histologic Variant?
Carcinoma of the Lung: A Really Dismal Histologic Variant? Dae Joon Kim, MD, Kil Dong Kim, MD, Dong Hwan Shin, MD, Jae Y Ro, MD, and Kyung Young Chung, MD Departments of Thoracic and Cardiovascular Surgery,
More informationInsulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens
Insulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens Kartik Viswanathan, M.D., Ph.D New York Presbyterian - Weill
More informationNeuroendocrine Lung Tumors Myers
Diagnosis and Classification of Neuroendocrine Lung Tumors Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of Michigan, Ann Arbor, MI myerjeff@umich.edu
More informationAlthough current American Cancer Society guidelines
ORIGINAL ARTICLE Diffuse Adenosis of the Peripheral Zone in Prostate Needle Biopsy and Prostatectomy Specimens Tamara L. Lotan, MD* and Jonathan I. Epstein, MD*w z Abstract: We have observed a group of
More informationCase Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland
Pathology International 2008; 58: 322 326 doi:10.1111/j.1440-1827.2008.02231.x Case Report Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland Hidetaka Yamamoto, 1 Hideoki Uryu,
More informationLUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering Cancer Center New York, NY PULMONARY NE TUMORS CLASSIFICATION
More informationCase 2. Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset
Case 2 Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset History 24 year old male presented with a 3 day history of right flank pain, sharp in nature Denies fever, chills, hematuria or
More informationSquamous Cell Carcinoma of Thyroid: possible thymic origin, so-called ITET/CASTLE 2012/03/22
Squamous Cell Carcinoma of Thyroid: possible thymic origin, so-called ITET/CASTLE 2012/03/22 History of ITET/CASTLE First Report Gross Appearance and Prognosis 1) Miyauchi A et al: Intrathyroidal epithelial
More informationImmunohistochemical Evaluation of Necrotic Malignant Melanomas
Anatomic Pathology / EVALUATION OF NECROTIC MALIGNANT MELANOMAS Immunohistochemical Evaluation of Necrotic Malignant Melanomas Daisuke Nonaka, MD, Jordan Laser, MD, Rachel Tucker, HTL(ASCP), and Jonathan
More informationNeuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $25.00 www.modernpathology.org Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationNeuroendocrine neoplasms of the lung
Neuroendocrine neoplasms of the lung M Papotti, L Righi, & M Volante University of Turin at San Luigi Hospital TORINO NETs OF THE LUNG Menu - Spectrum of NE lung tumors - CARCINOID TUMORS - SCLC /LCNEC
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationSmall Cell Carcinoma ex-pleomorphic Adenoma of the Parotid Gland
Head and Neck Pathol (2012) 6:502 506 DOI 10.1007/s12105-012-0376-1 CASE REPORT Small Cell Carcinoma ex-pleomorphic Adenoma of the Parotid Gland Ashley Cimino-Mathews Brian M. Lin Steven S. Chang Kofi
More informationEUROPEAN UROLOGY 64 (2013)
EUROPEAN UROLOGY 64 (213) 37 313 available at www.sciencedirect.com journal homepage: www.europeanurology.com Urothelial Cancer Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationCase year old female presented with asymmetric enlargement of the left lobe of the thyroid
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationCase 4 Diagnosis 2/21/2011 TGB
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationTHYMIC CARCINOMAS AN UPDATE
THYMIC CARCINOMAS AN UPDATE Mark R. Wick, M.D. University of Virginia Medical Center Charlottesville, VA CARCINOMA OF THE THYMUS General Clinical Features No apparent gender predilection Age range of 35-75
More informationDistinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical
More informationHuman Papillomavirus and Head and Neck Cancer. Ed Stelow, MD
Human Papillomavirus and Head and Neck Cancer Ed Stelow, MD No conflict of interest Declaration Cancer 1974 Lancet Oncol 2016; 17: e477-8 JAMA 1984; 252: 1857 JAMA 1988;259(13):1943-1944 Clin Cancer Res
More informationA 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.
November 2015 Case of the Month A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy. Contributed by: Rasha Salama, M.D., IU Department of Pathology and Laboratory Medicine
More informationBasaloid neoplasms of the head and neck. Basaloid SCC. Clinico-pathologic features 5/5/11. Basaloid Tumors Head and Neck
Basaloid neoplasms of the head and neck Richard Jordan DDS PhD FRCPath Professor & Director UCSF Oral Pathology Laboratory University of California San Francisco Basaloid Tumors Head and Neck Basaloid
More informationImpact of Histopathological Variant on the Outcome of Patients Treated by Radical Cystectomy
www.kjurology.org http://dx.doi.org/./kju... Original Article Urological Oncology http://crossmark.crossref.org/dialog/?doi=./kju...&domain=pdf&date_stamp= Impact of Histopathological Variant on the Outcome
More informationProblem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships
Differential of Neuroendocrine Carcinoma Alain C. Borczuk,MD Weill Cornell Medicine Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationGOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationGOBLET CELL CARCINOID
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationExpression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases
Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Peiguo G. Chu, M.D., Ph.D., Lawrence M. Weiss, M.D. Department of Pathology, City of Hope National Medical Center,
More informationSmall cell carcinoma of the kidney: a clinicopathologic study of 14 cases
Human Pathology (2011) 42, 1792 1798 www.elsevier.com/locate/humpath Original contribution Small cell carcinoma of the kidney: a clinicopathologic study of 14 cases Qiusheng Si MD, PhD a, Jane Dancer MD
More informationMicropapillary Urothelial Carcinoma of the Upper Urinary Tract Clinicopathologic Study of Five Cases
Anatomic Pathology / MICROPAPILLARY UROTHELIAL CARCINOMA Micropapillary Urothelial Carcinoma of the Upper Urinary Tract Clinicopathologic Study of Five Cases Delia Perez-Montiel, MD, 1,2 Ondrej Hes, MD,
More informationISSN X (Print) Original Research Article. DOI: /sjams
DOI: 10.21276/sjams.2016.4.7.33 Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2016; 4(7C):2468-2473 Scholars Academic and Scientific Publisher (An International Publisher
More informationIntraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance
& 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance Charles C Guo 1 and
More informationMucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging
More informationCase Report Pleomorphic Lymphoepithelioma-like Carcinoma of the Urinary Bladder
Int J Clin Exp Pathol (2009) 2, 194-199 www.ijcep.com/ijcep806002 Case Report Pleomorphic Lymphoepithelioma-like Carcinoma of the Urinary Bladder Oluwole Fadare 1, 2, Idris L. Renshaw 3 and Christopher
More informationImmunohistochemical Staining for Claudin-1 Can Help Distinguish Meningiomas From Histologic Mimics
Anatomic Pathology / CLAUDIN-1 IN MENINGIOMAS Immunohistochemical Staining for Claudin-1 Can Help Distinguish Meningiomas From Histologic Mimics Hejin P. Hahn, MD, PhD, Elizabeth A. Bundock, MD, PhD, and
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationPulmonary Salivary Gland Type Tumors With Features of Malignant Mixed Tumor (Carcinoma Ex Pleomorphic Adenoma) A Clinicopathologic Study of Five Cases
Anatomic Pathology / Pulmonary Salivary Gland Type Tumors Pulmonary Salivary Gland Type Tumors With Features of Malignant Mixed Tumor (Carcinoma Ex Pleomorphic Adenoma) A Clinicopathologic Study of Five
More informationCase: The patient is a 62 year old woman with a history of renal cell carcinoma that was removed years ago. A 2.4 cm liver mass was found on CT
Case: The patient is a 62 year old woman with a history of renal cell carcinoma that was removed years ago. A 2.4 cm liver mass was found on CT during follow- up. ALT, AST, Alk Phos and bilirubin were
More informationASSESSMENT OF GLEASON SYSTEM USE ON DIFFERENT TYPES OF PROSTATIC TISSUE SAMPLES
ASSESSMENT OF GLEASON SYSTEM USE ON DIFFERENT TYPES OF PROSTATIC TISSUE SAMPLES I. E. PLEŞEA*, B. ZAHARIA*, S. D. ENACHE**, G. MITROI***, P. TOMESCU***, O. T. POP*, P. BADEA****, A. KOŻOKIĆ***** *Department
More informationSarcomatoid Carcinoma of the Urinary Bladder: A Clinicopathological Study of 4 Cases and a Review of the Literature
www.kjurology.org DOI:10.4111/kju.2010.51.10.724 Case Report Sarcomatoid Carcinoma of the Urinary Bladder: A Clinicopathological Study of 4 Cases and a Review of the Literature Konstantinos Stamatiou,
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More informationSarcomatoid Carcinoma of Prostate: A Rare Entity
JOURNAL OF CASE REPORTS 2014;4(1):33-37 Sarcomatoid Carcinoma of Prostate: A Rare Entity PHILLIPS Adekoyejo Abiodun 1, DARAMOLA Adetola 1, ANUNOBI Charles 1, TIJANI Kehinde Habbeb 2, MOMOH Martins 1 Department
More informationNine cases of carcinoma with neuroendocrine features in the head and neck: clinicopathological characteristics and clinical outcomes
Japanese Journal of Clinical Oncology, 2015, 45(4) 328 335 doi: 10.1093/jjco/hyv008 Advance Access Publication Date: 10 February 2015 Original Article Original Article Nine cases of carcinoma with neuroendocrine
More informationRespiratory Tract Cytology
Respiratory Tract Cytology 40 th European Congress of Cytology Liverpool, UK Momin T. Siddiqui M.D. Professor of Pathology and Laboratory Medicine Director of Cytopathology Emory University Hospital, Atlanta,
More informationNeuroendocrine carcinomas (carcinoids) of the thymus
Neuroendocrine carcinomas (carcinoids) of the thymus Cesar A. Moran, MD Professor of Pathology Director of Thoracic Pathology M D Anderson Cancer Center Houston, TX Primary thymic neuroendocrine carcinomas
More informationClinical analysis of 29 cases of nasal mucosal malignant melanoma
1166 Clinical analysis of 29 cases of nasal mucosal malignant melanoma HUANXIN YU and GANG LIU Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Huanhu Hospital, Tianjin 300060, P.R. China
More informationDuctal adenocarcinoma of the prostate: A clinicopathological study
20 B. SATHESAN, S. A. S. GOONEWARDENA, H. W. D. ANURUDDHIKA AND M. V. C. DE SILVA Sri Lanka Journal of Urology, 2008, 9, 20-24 Original Article Ductal adenocarcinoma of the prostate: A clinicopathological
More informationACCME/Disclosures. Cribriform Lesions of the Prostate. Case
Cribriform Lesions of the Prostate Ming Zhou, MD, PhD Departments of Pathology and Urology New York University Langone Medical Center New York, NY Ming.Zhou@NYUMC.ORG ACCME/Disclosures The USCAP requires
More informationGenitourinary small cell carcinoma: 11 year treatment experience
(2014) 16, 705 709 2014 AJA, SIMM & SJTU. All rights reserved 1008-682X www.asiaandro.com; www.ajandrology.com Male Health Open Access ORIGINAL ARTICLE Genitourinary small cell carcinoma: 11 year treatment
More informationHistological Typing Of Cancer And Precancer Of The Oral Mucosa
Histological Typing Of Cancer And Precancer Of The Oral Mucosa 1 / 7 2 / 7 3 / 7 Histological Typing Of Cancer And Within the last decade, histologic grading has become widely accepted as a powerful indicator
More informationCombined Large Cell Neuroendocrine Carcinoma and Spindle Cell Carcinoma of the Lung
Case Reports Jpn J Clin Oncol 2011;41(6)797 802 doi:10.1093/jjco/hyr034 Advance Access Publication 16 March 2011 Combined Large Cell Neuroendocrine Carcinoma and Spindle Cell Carcinoma of the Lung Taichiro
More informationNEUROENDOCRINE DIFFERENTIATION IN EPITHELIAL TUMORS Marco Volante
NEUROENDOCRINE DIFFERENTIATION IN EPITHELIAL TUMORS Marco Volante University of Turin, San Luigi Hospital, Orbassano, Turin, Italy marco.volante@unito.it pure NE tum..a grey zone pure non-ne ca. 0% NE
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationp53 expression in invasive pancreatic adenocarcinoma and precursor lesions
Malaysian J Pathol 2011; 33(2) : 89 94 ORIGINAL ARTICLE p53 expression in invasive pancreatic adenocarcinoma and precursor lesions NORFADZILAH MY MBBCH,* Jayalakshmi PAILOOR MPath, FRCPath,* RETNESWARI
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationCutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
More informationPresentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More information2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections
european urology supplements 8 (2009) 453 457 available at www.sciencedirect.com journal homepage: www.europeanurology.com 2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms:
More informationProstatic stromal hyperplasia with atypia (PSHA) is a
Prostatic Stromal Hyperplasia With Atypia Follow-up Study of 18 Cases Deloar Hossain, MD, FRCPC; Isabelle Meiers, MD; Junqi Qian, MD; Gregory T. MacLennan, MD; David G. Bostwick, MD, MBA Context. Prostatic
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationImmunohistochemical Profile of Lung Tumors in Image Guided Biopsies
Original Article DOI: 10.21276/APALM.1342 Immunohistochemical Profile of Lung Tumors in Image Guided Biopsies T. Pavithra 1 *, A. Dhanalakshmi 1, C. Lalitha 1, K.B. Lavanya 1 and S. Shifa 2 Department
More informationPrimary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings
CASE REPORT Primary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings Makoto Nagashima 1, Ayako Moriyama 1, Yasuo
More informationUrothelial Carcinoma With Squamous Differentiation Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis
Pathology Report With Squamous Is Associated With High Tumor Stage and Pelvic Lymph-Node Metastasis Yunguang Liu, MD, PhD, Marilyn M. Bui, MD, and Bo Xu, MD, PhD Background: Squamous differentiation occurs
More informationHyperplastic, Premalignant and Malignant Lesions of the Prostate Gland
Jehoram Tei Anim, md, FRCPath; Sitara Abdul Sathar, MB; Mohammed Ejaz Bhatti, MSc From the Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait. Address reprint requests and correspondence
More informationImmunohistochemistry and Bladder Tumours
Immunohistochemistry and Bladder Tumours Dr. Andrew J. Evans MD PhD FRCPC Consultant in Genitourinary Pathology University Health Network Toronto, ON Objec ves Review markers of urothelial differen a on
More information5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.
Common Differential Diagnoses in Urological Pathology Jonathan I. Epstein Prostate Adenocarcinoma vs. Urothelial Carcinoma 1 2 NKX3.1 NKX3.1 3 4 5 6 Proposed ISUP Recommendations Option to use PSA as a
More informationCarcinoma of the Urinary Bladder Histopathology
Carcinoma of the Urinary Bladder Histopathology Reporting Proforma (Radical & Partial Cystectomy, Cystoprostatectomy) Includes the International Collaboration on Cancer reporting dataset denoted by * Family
More informationMicrocystic transitional cell carcinoma: a rare tumor of the urinary bladder
PATHOLOGICA 2017;109:151-155 Case report Microcystic transitional cell carcinoma: a rare tumor of the urinary bladder M. TRIKI 1, L. AYADI 1, R. KALLEL 1, S. CHARFI 1, I. SAGUEM 1, N. MHIRI 2, T.S. BOUDAWARA
More informationMu ath M.A. Rjoub Supervised by: Dr. Huda Zahawi, FRCPath. King Abdullah University Hospital )KAUH(
Mu ath M.A. Rjoub Supervised by: Dr. Huda Zahawi, FRCPath. King Abdullah University Hospital )KAUH( Clinical History A 56 year old single female, presented complaining of postmenopausal bleeding. She underwent
More informationProstatic ductal adenocarcinoma is a subtype of
ORIGINAL ARTICLE High-grade Prostatic Intraepithelial Neoplasialike Ductal Adenocarcinoma of the Prostate: A Clinicopathologic Study of 28 Cases Fabio Tavora, MD* and Jonathan I. Epstein, MD*w z Abstract:
More information4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
More informationMetastatic Ductal Adenocarcinoma of the Prostate Cytologic Features and Clinical Findings
Anatomic Pathology / FNA OF METASTATIC PROSTATIC DUCTAL ADENOCARCINOMA Metastatic Ductal Adenocarcinoma of the Prostate Cytologic Features and Clinical Findings Yun Gong, MD, Nancy Caraway, MD, John Stewart,
More informationNeuroendocrine (NE) lung tumors represent a broad
Large Cell Neuroendocrine Carcinoma of the Lung: A 10-Year Clinicopathologic Retrospective Study Massimiliano Paci, MD, Alberto Cavazza, MD, Valerio Annessi, MD, Innocenza Putrino, MD, Guglielmo Ferrari,
More informationhgh and GHR Expression in Large Cell Neuroendocrine Carcinoma of the Colon and Rectum
hgh and GHR Expression in Large Cell Neuroendocrine Carcinoma of the Colon and Rectum ZORAN JUKIĆ 1, RINË LIMANI 2, LUMTURIJE GASHI LUCI 2, VIVIAN NIKIĆ 3, AUGUST MIJIĆ 4, DAVOR TOMAS 3,5 and BOŽO KRUŠLIN
More informationPathology of the Thyroid
Pathology of the Thyroid Thyroid Carcinoma Arising from Follicular Cells 2015-01-19 Prof. Dr. med. Katharina Glatz Pathologie Carcinomas Arising from Follicular Cells Differentiated Carcinoma Papillary
More informationCase 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:
Case 18 M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is: A. Pilomatrical carcinoma B. Adnexal carcinoma NOS C. Metastatic squamous cell carcinoma D.Primary squamous cell carcinoma
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationHistologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer
REVIEW Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer Venu Chalasani, MD; Joseph L. Chin, MD, FRCSC; Jonathan I. Izawa, MD, FRCSC Abstract Bladder cancer
More informationUnknown Slides Conference
Unknown Slides Conference Jae Y. Ro, MD, PhD Weill Medical College of Cornell Univ. The Methodist Hospital, and UT MD Anderson Cancer Center Houston, TX November 9, 2013 Amman, Jordan 25 th Congress of
More informationOriginal Article Prognostic role of neuroendocrine cell differentiation in human gastric carcinoma
Int J Clin Exp Med 2015;8(5):7837-7842 www.ijcem.com /ISSN:1940-5901/IJCEM0003844 Original Article Prognostic role of neuroendocrine cell differentiation in human gastric carcinoma Tingting Zhang, Dan
More information3/27/2017. Pulmonary Pathology Specialty Conference. Disclosure of Relevant Financial Relationships. Clinical History:
Pulmonary Pathology Specialty Conference Saul Suster, M.D. Medical College of Wisconsin Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position
More informationSynonyms. Nephrogenic metaplasia Mesonephric adenoma
Nephrogenic Adenoma Synonyms Nephrogenic metaplasia Mesonephric adenoma Definition Benign epithelial lesion of urinary tract with tubular, glandular, papillary growth pattern Most frequently in the urinary
More information